Headquarters

Thousand Oaks, California

Staff

Approximately
31,500 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2025 Financial Highlights

Total revenue
$36.8 billion

Product sales
$35.1 billion

R&D investment
$7.3 billion

Address/Phone

One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Main
805.447.1000

Investors
805.447.1060

About Amgen
Our Mission: To Serve Patients

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines, helping make people's lives easier, fuller and longer.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat heart disease, obesity and obesity-related conditions, rare diseases, inflammatory conditions and cancer.

Amgen has been consistently recognized for innovation and workplace culture, including honors from *Fast Company* and *Forbes*. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Products

ACTIMMUNE® (Interferon gamma-1b)

Aimovig® (erenumab-aooe)

AMJEVITA® (adalimumab-atto)

Aranesp® (darbepoetin alfa)

AVSOLA® (infliximab-axxq)

BKEMV® (eculizumab-aeeb)

BLINCYTO® (blinatumomab)

Enbrel® (etanercept)

EPOGEN® (epoetin alfa)

EVENITY® (romosozumab-aqqg)

IMDELLTRA® (tarlatamab-dlle)

IMLYGIC® (talimogene laherparepvec)

KANJINTI® (trastuzumab-anns)

KRYSTEXXA® (pegloticase)

KYPROLIS® (carfilzomib)

LUMAKRAS® (sotorasib)

MVASI® (bevacizumab-awwb)

Neulasta® (pegfilgrastim)

NEUPOGEN® (filgrastim)

Nplate® (romiplostim)

Otezla® (apremilast)

Parsabiv® (etelcalcetide)

Pavblu® (aflibercept-ayyh)

PROCYSBI® (cysteamine bitartrate)

Prolia® (denosumab)

RAVICTI® (glycerol phenylbutyrate)

Repatha® (evolocumab)

RIABNI® (rituximab-arrx)

TAVNEOS® (avacopan)

TEPEZZA® (teprotumumab-trbw)

TEZSPIRE® (tezepelumab-ekko)

UPLIZNA® (inebilizumab-cdon)

Vectibix® (panitumumab)

WEZLANA™ (ustekinumab-auub)

XGEVA® (denosumab)

Certain products are developed in collaboration with a third-party. For information about our pipeline and therapies, visit www.amgen.com.

REACHING SERIOUSLY ILL PATIENTS WORLDWIDE

We have a presence in approximately 100 countries worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas: general medicine, rare disease, inflammation and oncology, delivering innovative medicines to help people live longer, fuller, happier lives.

ACCELERATING THERAPIES FOR PATIENTS WITH CUTTING-EDGE SCIENCE

We combine our understanding of human genetics and disease biology with advanced science and technologies, like protein engineering and AI capabilities, to work to identify and potentially deliver the most effective treatments for people living with some of the world's toughest diseases.

MAKING MEDICINES SAFELY AND RELIABLY

Many of Amgen's medicines are made through a highly complex process involving living cells. We aim to deliver for "every patient, every time," and we have a long-running reputation for the reliability of our supply chain.

OPERATING RESPONSIBLY

Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines. We also help build a better world by focusing on corporate sustainability issues that matter most to our business and our stakeholders.

THE AMGEN FOUNDATION

The Amgen Foundation is inspiring the next generation of scientists and future problem solvers, providing best-in-class science education at no cost to students through its signature programs, including LabXchange, Amgen Scholars, and the Amgen Biotech Experience. To date, the Foundation has donated more than $500 million to local, regional, and international non-profits that impact society in inspiring and innovative ways.

Investor Information: Certain information in this fact sheet is based on disclosures contained in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. Additional information may be found in those filings and press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on http://investors.amgen.com. The information in this fact sheet is given as of February 13, 2026, and Amgen does not undertake any obligation to update any information in this document.